Effect of oral propranolol on periocular Capillary Hemangiomas of Infancy

Koka, Kirthi; Mukherjee, Bipasha; Agarkar, Sumita

doi:10.1016/j.pedneo.2017.11.021

Cited by 14 publications

(20 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…12 Leaute-Labreze in 2008, incidentally found that oral propranolol has an excellent role in treatment of infantile haemangioma, while they were treating pediatric cardiac patients. 5,8,14 Since then Systemic propranolol is a new treatment modality for infantile haemangioma. In our study, age of the patient ranged from 1-42 months (mean 5.8 months).…”

Section: Discussionmentioning

confidence: 99%

“…Infantile capillary haemangioma is considered a hamartoma and represents one of the most common benign vascular tumour in children. 3,8,10,11 This lesion may noticed at birth as a reddish spot (30-35%) or develops a few weeks after birth 5 that enlarges during first months of life, and then maintains its size or involutes (50%) at fifth year of age. 10 The female to male ratio is 3:1.…”

Section: Introductionmentioning

confidence: 99%

“…3 The lesion typically involute before the end of the first decade, so treatment is usually not required. 2,8 Treatment is indicated when obstruction of visual axis or astigmatism causing amblyopia, exposure keratitis secondary to proptosis, optic nerve compression, ulceration, bleeding and facial disfigurement present. 1,3,9 Most common treatment options are intralesional or systemic steroids, interferon alpha, vincristine, laser therapy or surgical excision.…”

Section: Introductionmentioning

confidence: 99%

“…1,5,9,15 Oral propranolol, a non-selective βblocker is now considered as highly promising agent for the treatment of capillary haemangioma which inhibit vascular proliferation. 3,5,8 The aim of this study is to assess the use of oral propranolol in the treatment of Infantile hemangioma, quantifying its effectiveness and safety under continuous monitoring.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Oral propranolol in the treatment of infantile eyelid haemangioma

2020

IJOOO

View full text Add to dashboard Cite

Introduction: Capillary haemangiomas or infantile haemangioma of the eyelid are the most common tumors of infancy. Infantile haemangioma appears soon after birth. Tumors that involving the periorbital area require treatment. Objectives: To evaluate the rate of regression by size and to evaluate color change of infantile eyelid haemangioma treated with oral propranolol. Methods: The prospective study was carried out in the department of Oculoplasty, Ispahani Islamia Eye Institute and hospital during the period of January 01, 2013 to September 30, 2017. We included all patients of 1 months to 60 months, clinically diagnosed infantile eyelid haemangioma of either sex attended in the out-patient department during the study period with relative indication for treatment. The exclusion criteria were: haemangioma with presenting life-threatening condition, cardiovascular disorders contraindicating propranolol use, family history of bronchial asthma, or recent/repeated outbreak of wheezing, low birth weight newborns and previously treated with intralesional Triamcinolone. Patients were treated by oral Propranolol: 2 mg/ kg /day. Follow-up visits were initially scheduled after 2 and 4 weeks of therapy and then monthly for six months. Results: This study included a total of 93 patients with infantile eyelid haemangioma. The age of the patients in the study group ranged from 1 months to 42 months. Male 36 and female 57. Right eye involved in 40 patients and left eye 53. After 6 months of treatment, overall color clearance was seen in all patients, 70(75%) had an excellent response. After 6 months of treatment, overall regression of size was seen in all patients. In 75(80%) patient had an excellent response. Conclusion: Propranolol has been found clinically effective and also cost-effective in the treatment of infantile eyelid haemangioma. It also demonstrated better tolerance with minimal adverse effects.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Oral propranolol in the treatment of infantile eyelid haemangioma

2020

IJOOO

View full text Add to dashboard Cite

show abstract

“…Currently available treatments include: systemic use of β-blockers, corticosteroids, interferon α, vincristine, angiotensin-converting enzyme blockers, as well as topical β-blockers, corticosteroids, imiquimod, injection of corticosteroids [5,17]. Among these methods, the most studied are systemic treatment and topical application of β-blockers, which have shown good results [18,19]. Other local treatments include: laser therapy (dye lasers, neodymium laser, argon and CO 2 laser), surgical removal, embolization and compression therapy [20][21][22].…”

Section: Suggested Solution To the Problemmentioning

confidence: 99%

Particularities of the Course and Treatment Hemangiomas of Different Morphological Types in Children and Their Association With Soluble Forms of Fas and Fasl

Vivcharuk

2020

ScienceRise

View full text Add to dashboard Cite

The article discusses analysis of examinations and treatment results 100 children with hemangiomas different localizations on the different stages of existence. The study included patients of different ages, from birth to 6 years. Importance of primary assessment of severity and activity of hemangioma`s, for the choice of treatment, was considered. Correlation between clinical course of hemangiomas and soluble Fas/FasL was analyzed. The object of the research: Clinical course of hemangiomas of different morphological types, soluble form of Fas and FasL in the serum of patients with hemangiomas. Investigated problem: Improving the results of treatment of hemangiomas in children. The main scientific results: Predicting the course of hemangiomas in children allows to determine the need for treatment at different stages of their existence, as well as to carry out timely correction of the prescribed treatment to achieve good cosmetic and functional results. The area of practical use of the research results: Department of Pediatrics, Pediatric Surgery, Dermatology. Innovative technological product: Defined characteristics will help in predicting the course of hemangiomas and the effectiveness of their treatment. Scope of the innovative technological product: Clinical pediatric practice.

show abstract